Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus

Abstract

AbstractIntroductionInsulin resistance and obesity have been associated with irisin, a protein in fat cells. The levels of irisin in patients with type 2 diabetes mellitus (T2DM) were significantly lower than those in non‐diabetics. This study aimed to examine the relationship between serum irisin levels and endothelial dysfunction in patients with T2DM.MethodsThere were 90 participants in this study. We matched 65 patients with T2DM with 25 healthy control participants. A series of tests were performed on the participants, including fasting blood glucose, 2 hours postprandial blood glucose, glycated haemoglobin, triglycerides (TG), total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), TG/HDL‐C ratio and albumin/creatinine ratio. In addition to measuring high‐sensitivity C‐reactive protein (hs‐CRP). Enzyme‐linked immunosorbent assay (ELISA) technique was used for estimating irisin concentrations.ResultsFlow‐mediated dilation (FMD) was significantly lower in patients with T2DM; however, there was a non‐statistically significant difference between healthy controls and patients with T2DM regarding serum Irisin level. CRP and LDL levels were inversely correlated with circulating irisin levels. In a stepwise regression analysis, only the hs‐CRP and LDL were statistically significant in predicting irisin level.ConclusionsIn patients with T2DM, serum levels of irisin were inversely correlated with hyperglycaemia, body mass index and per cent body fat; this suggests that detecting irisin levels early can prevent cardiovascular diseases from progressing. According to the study results, serum irisin serves as a predictive marker for early cardiovascular disease, thus preventing the disease from progressing. There is a need for further research in order to understand how irisin contributes to the development of atherosclerosis and the development of diabetic complications.